Joerg Heyer - Palisade Bio Head Medicine
| PALI Stock | USD 1.04 0.03 2.97% |
Executive
Joerg Heyer is Head Medicine of Palisade Bio
| Address | 7750 El Camino Real, Carlsbad, CA, United States, 92009 |
| Phone | 858 704 4900 |
| Web | https://www.palisadebio.com |
Palisade Bio Management Efficiency
The company has return on total asset (ROA) of (0.8094) % which means that it has lost $0.8094 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7072) %, meaning that it created substantial loss on money invested by shareholders. Palisade Bio's management efficiency ratios could be used to measure how well Palisade Bio manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.39. The current Return On Capital Employed is estimated to decrease to -2.04. As of now, Palisade Bio's Net Tangible Assets are increasing as compared to previous years. The Palisade Bio's current Fixed Asset Turnover is estimated to increase to 2.50, while Non Current Assets Total are projected to decrease to under 366.7 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Stefan Sperl | Kiora Pharmaceuticals | N/A | |
| John Kowalczyk | Nuwellis | N/A | |
| Marshall Woodworth | MetaVia | 67 | |
| Robert Homolka | MetaVia | N/A | |
| Eric Hyllengren | Zura Bio Limited | 50 | |
| Stephen McAndrew | Sonnet Biotherapeutics Holdings | 71 | |
| Theresa Lowry | Zura Bio Limited | 51 | |
| Paul Wotta | Nuwellis | 67 | |
| Vitaliy Epshteyn | Nuwellis | 46 | |
| Gael Hedou | Sonnet Biotherapeutics Holdings | 53 | |
| Melissa CPA | Kiora Pharmaceuticals | 45 | |
| Kiran MBBS | Zura Bio Limited | 52 | |
| Michael Pine | MetaVia | 49 | |
| FACC MD | Nuwellis | N/A | |
| Christopher MD | MetaVia | N/A | |
| Linda Mahoney | Phio Pharmaceuticals Corp | N/A | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 54 | |
| Esq JD | Cardio Diagnostics Holdings | 60 | |
| FACC MBA | Nuwellis | N/A | |
| MiKyung Kim | MetaVia | N/A | |
| Verender Badial | Zura Bio Limited | 52 | |
Management Performance
| Return On Equity | -1.71 | ||||
| Return On Asset | -0.81 |
Palisade Bio Leadership Team
Elected by the shareholders, the Palisade Bio's board of directors comprises two types of representatives: Palisade Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Palisade. The board's role is to monitor Palisade Bio's management team and ensure that shareholders' interests are well served. Palisade Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Palisade Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joerg Heyer, Head Medicine | ||
| Ryker Willie, Senior Controller | ||
| J Finley, CEO Director | ||
| Sharon McBrayer, Director Operations | ||
| Mitchell MD, Chief Officer | ||
| Robert McRae, VP Devel | ||
| MD FAAAAI, Chief Officer |
Palisade Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Palisade Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.71 | ||||
| Return On Asset | -0.81 | ||||
| Current Valuation | (2.07 M) | ||||
| Shares Outstanding | 4.8 M | ||||
| Shares Owned By Insiders | 0.46 % | ||||
| Shares Owned By Institutions | 5.43 % | ||||
| Number Of Shares Shorted | 813.86 K | ||||
| Price To Earning | 0.16 X | ||||
| Price To Book | 0.96 X | ||||
| Price To Sales | 14.03 X |
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Palisade Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palisade Bio. If investors know Palisade will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palisade Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Palisade Bio is measured differently than its book value, which is the value of Palisade that is recorded on the company's balance sheet. Investors also form their own opinion of Palisade Bio's value that differs from its market value or its book value, called intrinsic value, which is Palisade Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palisade Bio's market value can be influenced by many factors that don't directly affect Palisade Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Palisade Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Palisade Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palisade Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.